Gilead Sciences

Amgen

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Alnylam Pharmaceuticals

Illumina

Biogen

United Therapeutics

Moderna

Viatris

Invesco Nasdaq Biotechnology ETF

IBBQ tracks a modified market-cap-weighted index of US biotechnology and pharmaceutical companies listed on the NASDAQ.

The Invesco Nasdaq Biotechnology ETF (IBBQ) is just a few weeks old, but even with that rookie status, it could be a stellar second half idea. On the back of the Food and Drug Administration (FDA) conditionally approving Biogen's (NASDAQ: BIIB) Alzheimer's drug, Aduhelm, the Nasdaq Biotechnology Index (NBI) – IBBQ's underlying index – surged [.

New Biotechnology ETF Could Be a Stellar Second Half Idea

As investors consider the regulatory, scientific, and demographic factors driving today's growth in biotechnology industry, they can look to the Nasdaq Biotechnology Index's methodology and one related exchange traded fund, which could lead to the best representation of the sector. In the recent webcast, The Biotech Trek: A Short History from 1993 to 2021, Mark [.

A Biotech ETF to Track Nasdaq's Industry-Setting Benchmark

The Nasdaq Biotechnology Index (NBI) launched in 1993, when the industry was still in the midst of the original “biotech revolution.” Since then, its constituent basket has swelled from roughly 100 components to 274, reflecting the tremendous growth in the small cap space – the overwhelming majority of which has stemmed from IPOs on the [.

News for Invesco Nasdaq Biotechnology ETF ETF (IBBQ)